{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:35:31Z","timestamp":1761773731643,"version":"build-2065373602"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00347-025-02311-w","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T08:47:33Z","timestamp":1755938853000},"page":"890-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Langzeitverlauf nach photodynamischer Therapie bei persistierender Chorioretinopathia centralis serosa","Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy"],"prefix":"10.1007","volume":"122","author":[{"given":"Anna","family":"Kisk\u00e4mper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Augstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"von Schwarzkopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannik","family":"Laich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Rothaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Janning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurenz","family":"Pauleikhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Retina.Net CCS-Register-Studiengruppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"2311_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/OPTH.S115685","volume":"11","author":"MB Breukink","year":"2017","unstructured":"Breukink\u00a0MB, Dingemans\u00a0AJ, den Hollander\u00a0AI et\u00a0al (2017) Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol 11:39\u201346. https:\/\/doi.org\/10.2147\/OPTH.S115685","journal-title":"Clin Ophthalmol"},{"key":"2311_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/IAE.0000000000001138","volume":"37","author":"C-K Cheng","year":"2017","unstructured":"Cheng\u00a0C\u2011K, Chang\u00a0C\u2011K, Peng\u00a0C\u2011H (2017) Comparison of photodynamic therapy using half-dose OF verteporfin or half-fluence of laser light for the treatment OF chronic central serous chorioretinopathy. Retina 37:325\u2013333. https:\/\/doi.org\/10.1097\/IAE.0000000000001138","journal-title":"Retina"},{"key":"2311_CR3","doi-asserted-by":"publisher","unstructured":"Chhablani J, Cohen FB Central Serous Chorioretinopathy International Group (2020) Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. Ophthalmol Retin 4:1043\u20131046. https:\/\/doi.org\/10.1016\/j.oret.2020.07.026","DOI":"10.1016\/j.oret.2020.07.026"},{"key":"2311_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3341\/kjo.2015.29.5.331","volume":"29","author":"P Cidad","year":"2015","unstructured":"Cidad\u00a0P, Gonz\u00e1lez\u00a0E, Asencio\u00a0M, Garc\u00eda\u00a0J (2015) Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy. Korean J Ophthalmol 29:331\u2013335. https:\/\/doi.org\/10.3341\/kjo.2015.29.5.331","journal-title":"Korean J Ophthalmol"},{"key":"2311_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich\u00a0A, Matet\u00a0A, Dirani\u00a0A et\u00a0al (2015) Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82\u2013118. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"2311_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aos.15263","volume":"101","author":"EHC van Dijk","year":"2023","unstructured":"van Dijk\u00a0EHC, Feenstra\u00a0HMA, Bjerager\u00a0J et\u00a0al (2023) Comparative efficacy of treatments for chronic central serous chorioretinopathy: A\u00a0systematic review with network meta-analyses. Acta Ophthalmol 101:140\u2013159. https:\/\/doi.org\/10.1111\/aos.15263","journal-title":"Acta Ophthalmol"},{"key":"2311_CR7","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.3390\/diagnostics13172792","volume":"13","author":"O Esteban-Flor\u00eda","year":"2023","unstructured":"Esteban-Flor\u00eda\u00a0O, P\u00e9rez-Rivas\u00e9s\u00a0G, Honrubia-Grijalbo\u00a0A et\u00a0al (2023) Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Diagnostics 13:2792. https:\/\/doi.org\/10.3390\/diagnostics13172792","journal-title":"Diagnostics"},{"key":"2311_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/IAE.0000000000003686","volume":"43","author":"HMA Feenstra","year":"2023","unstructured":"Feenstra\u00a0HMA, Diederen\u00a0RMH, Lamme\u00a0MJCM et\u00a0al (2023) Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy. Retina 43:379\u2013388. https:\/\/doi.org\/10.1097\/IAE.0000000000003686","journal-title":"Retina"},{"key":"2311_CR9","doi-asserted-by":"publisher","unstructured":"Haga\u00a0F, Maruko\u00a0R, Sato\u00a0C,  Kataoka\u00a0K, Ito\u00a0Y, Terasaki\u00a0H\u00a0(2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A\u00a03-year follow-up study. PLoS ONE 12:1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0181479","DOI":"10.1371\/journal.pone.0181479"},{"key":"2311_CR10","doi-asserted-by":"publisher","first-page":"13286","DOI":"10.1038\/s41598-021-92693-z","volume":"11","author":"Y-C Hu","year":"2021","unstructured":"Hu\u00a0Y\u2011C, Chen\u00a0Y\u2011L, Chen\u00a0Y\u2011C, Chen\u00a0S\u2011N (2021) 3\u2011year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization. Sci Rep 11:13286. https:\/\/doi.org\/10.1038\/s41598-021-92693-z","journal-title":"Sci Rep"},{"key":"2311_CR11","doi-asserted-by":"crossref","unstructured":"Hwang S, Noh H, Kang SW et\u00a0al (2021) Choroidal neovascularization secondary to photodynamic therapy for central serous chorioretinopathy: Incidence, Risk Factors, and Clinical Outcomes. Retina 41:","DOI":"10.1097\/IAE.0000000000003067"},{"key":"2311_CR12","doi-asserted-by":"publisher","first-page":"3190136","DOI":"10.1155\/2020\/3190136","volume":"2020","author":"T Iwase","year":"2020","unstructured":"Iwase\u00a0T, Yokouchi\u00a0H, Kitahashi\u00a0M et\u00a0al (2020) Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy. Biomed Res Int 2020:3190136. https:\/\/doi.org\/10.1155\/2020\/3190136","journal-title":"Biomed Res Int"},{"key":"2311_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/eye.2013.24","volume":"27","author":"SH Karakus","year":"2013","unstructured":"Karakus\u00a0SH, Basarir\u00a0B, Pinarci\u00a0EY et\u00a0al (2013) Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond) 27:612\u2013620. https:\/\/doi.org\/10.1038\/eye.2013.24","journal-title":"Eye (Lond)"},{"key":"2311_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","volume":"170","author":"FHP Lai","year":"2016","unstructured":"Lai\u00a0FHP, Ng\u00a0DS, Bakthavatsalam\u00a0M et\u00a0al (2016) A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Am J Ophthalmol 170:91\u201399. https:\/\/doi.org\/10.1016\/j.ajo.2016.07.026","journal-title":"Am J Ophthalmol"},{"key":"2311_CR15","first-page":"T8","volume":"113","author":"TYY Lai","year":"2015","unstructured":"Lai\u00a0TYY, Wong\u00a0RLM, Chan\u00a0W\u2011M (2015) Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 113:T8","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2311_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jfo.2015.02.007","volume":"38","author":"E Leys","year":"2015","unstructured":"Leys\u00a0E, Tuttle\u00a0S, Rasquin\u00a0F et\u00a0al (2015) Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy. J\u00a0Fr Ophtalmol 38:709\u2013716. https:\/\/doi.org\/10.1016\/j.jfo.2015.02.007","journal-title":"J Fr Ophtalmol"},{"key":"2311_CR17","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S174573","volume":"12","author":"D Mohabati","year":"2018","unstructured":"Mohabati\u00a0D, van Dijk\u00a0EH, van Rijssen\u00a0TJ et\u00a0al (2018) Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy. Clin Ophthalmol 12:2167\u20132176. https:\/\/doi.org\/10.2147\/OPTH.S174573","journal-title":"Clin Ophthalmol"},{"key":"2311_CR18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3928\/23258160-20191119-03","volume":"50","author":"YJ Park","year":"2019","unstructured":"Park\u00a0YJ, Kim\u00a0Y\u2011K, Park\u00a0KH, Woo\u00a0SJ (2019) Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 50:760\u2013770. https:\/\/doi.org\/10.3928\/23258160-20191119-03","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2311_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s00347-023-01825-5","volume":"120","author":"L Pauleikhoff","year":"2023","unstructured":"Pauleikhoff\u00a0L, Rothaus\u00a0K, Gro\u00df-B\u00f6lting\u00a0F et\u00a0al (2023) Photodynamische Therapie in Deutschland \u2013 Quo vadis? Die Ophthalmol 120:818\u2013824. https:\/\/doi.org\/10.1007\/s00347-023-01825-5","journal-title":"Die Ophthalmol"},{"key":"2311_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/112067210901900126","volume":"19","author":"M Reibaldi","year":"2009","unstructured":"Reibaldi\u00a0M, Boscia\u00a0F, Avitabile\u00a0T et\u00a0al (2009) Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy. Eur J Ophthalmol 19:154\u2013158. https:\/\/doi.org\/10.1177\/112067210901900126","journal-title":"Eur J Ophthalmol"},{"key":"2311_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00417-020-04959-3","volume":"259","author":"TJ van Rijssen","year":"2021","unstructured":"van Rijssen\u00a0TJ, van Dijk\u00a0EHC, Scholz\u00a0P et\u00a0al (2021) Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy. Graefes Arch Clin Exp Ophthalmol 259:905\u2013910. https:\/\/doi.org\/10.1007\/s00417-020-04959-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2311_CR22","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen\u00a0TJ, van Dijk\u00a0EHC, Yzer\u00a0S et\u00a0al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003","journal-title":"Prog Retin Eye Res"},{"key":"2311_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5301\/ejo.5000051","volume":"22","author":"A Rouvas","year":"2012","unstructured":"Rouvas\u00a0A, Stavrakas\u00a0P, Theodossiadis\u00a0PG et\u00a0al (2012) Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol 22:417\u2013422. https:\/\/doi.org\/10.5301\/ejo.5000051","journal-title":"Eur J Ophthalmol"},{"key":"2311_CR24","doi-asserted-by":"publisher","first-page":"e1522","DOI":"10.1111\/aos.15148","volume":"100","author":"MJ Sirks","year":"2022","unstructured":"Sirks\u00a0MJ, van Dijk\u00a0EHC, Rosenberg\u00a0N et\u00a0al (2022) Clinical impact of the worldwide shortage of verteporfin (Visudyne\u00ae) on ophthalmic care. Acta Ophthalmol 100:e1522\u2013e1532. https:\/\/doi.org\/10.1111\/aos.15148","journal-title":"Acta Ophthalmol"},{"key":"2311_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000490773","volume":"241","author":"BK Son","year":"2019","unstructured":"Son\u00a0BK, Kim\u00a0K, Kim\u00a0ES, Yu\u00a0S\u2011Y (2019) Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmologica 241:105\u2013115. https:\/\/doi.org\/10.1159\/000490773","journal-title":"Ophthalmologica"},{"key":"2311_CR26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/bjophthalmol-2014-305353","volume":"99","author":"C-C Tseng","year":"2015","unstructured":"Tseng\u00a0C\u2011C, Chen\u00a0S\u2011N (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99:1070\u20131077. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305353","journal-title":"Br J Ophthalmol"},{"key":"2311_CR27","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1038\/s41598-019-45080-8","volume":"9","author":"J-S Wu","year":"2019","unstructured":"Wu\u00a0J\u2011S, Chen\u00a0S\u2011N (2019) Optical Coherence Tomography Angiography for Diagnosis of Choroidal Neovascularization in Chronic Central Serous Chorioretinopathy after Photodynamic Therapy. Sci Rep 9:9040. https:\/\/doi.org\/10.1038\/s41598-019-45080-8","journal-title":"Sci Rep"},{"key":"2311_CR28","unstructured":"Yaman A, Arikan G, Saatci AO, Cingil G (2007) Choroidal neovascularization following photodynamic therapy in a\u00a0patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol: 69\u201373"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02311-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02311-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02311-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:33:15Z","timestamp":1761773595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02311-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2311"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02311-w","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Kisk\u00e4mper, M.\u00a0Augstein, C.\u00a0von Schwarzkopf, Y.\u00a0Laich, K.\u00a0Rothaus, C.\u00a0Janning, L.\u00a0Pauleikhoff und C.\u00a0Lange geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}